Company Overview and News

10
HSBC plans wealth hiring spree in CEO's bet on Asia's rich

2018-09-18 theedgemarkets
(Sept 18): HSBC Holdings Plc is planning to increase its wealth-management staff in Asia, as Chief Executive Officer John Flint bets on growth in the region.
DGLD HSNGF CS 0011 HSB D05 UGLD HSNGY UBS DBSDF HSBC HBCYF DBSDY DSLV C VIIX BHKLY CSSLF VIIZ 2388 HCS 0005 CSGKF CGBBW BNKHF HSEA HSEB ZIV USLV TVIX ULSGF XIV

 
BOC Hong Kong (Holdings) Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2018-08-30 seekingalpha
The following slide deck was published by BOC Hong Kong (Holdings) Ltd. ADR in conjunction with their 2018 Q2 earnings call.
BHKLY BNKHF 2388

 
Asia Markets: Asian markets mostly extend this week’s gains

2018-08-29 marketwatch
Asian stock markets mostly extended gains to a third straight day early Wednesday, following little movement overnight in the U.S. and Europe.
BHKLY BNKHF 2388

 
One of Asia’s Biggest Private Banks Goes on a Hiring Spree - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BHKLY BNKHF 2388

 
Newbie Among Asia's Biggest Private Banks Aims to Ramp Up Hiring

2018-06-20 theedgemarkets
(June 21): BOC Hong Kong (Holdings) Ltd., which broke into the ranks of the 20 biggest private banks in Asia four years after getting into the business, is stepping up its expansion in the region.
BHKLY BNKHF 2388

 
Hong Kong’s dim sum bond market to pivot towards eco-friendly fundraising

2018-06-18 scmp
The Hong Kong government is seeking to revive investor interest in offshore yuan bonds issued in the city by emphasising their role in helping to finance ventures related to the green economy and environmental sustainability.
BHKLY 55BC BNKHF 2388 CBQS

2
Hong Kong currency defense kills fixed-rate mortgage market

2018-04-20 japantimes.co.jp
HONG KONG – Hong Kong’s banks, blindsided by rising funding costs due to the city’s costly defense of its currency peg, are clamping down on popular fixed-rate mortgages.
BHKLY 55BC 2388 CBQS HCS HSB 0005 BNKHF HSEA HSEB HSBC HBCYF

2
Hong Kong's Currency Defense Kills Fixed-Rate Mortgage Market - Bloomberg

2018-04-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HSB 0005 BHKLY BNKHF HSEA HSEB 2388 HCS HSBC HBCYF

 
Hong Kong and mainland stocks drop as tech shares rout, trade war fears continue

2018-04-03 scmp
Hong Kong and mainland stocks declined, tracking a global sell-off after US President Donald Trump’s criticism of Amazom.com and China’s retaliatory tariffs weighed on equities.
WWNTY BHKLY WWNTF BNKHF HGKGF 0151 HGKGY 2388

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...